Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

625
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
625
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

450
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
450
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

627
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
627
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

2.8K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.8K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

954
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
954

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Percutaneous Retrieval of a Migrated Iliac Vein Stent Traversing the Tricuspid Valve.

JACC. Case reports·2026
Same author

Outcomes of Percutaneous Interventions for Aortic Coarctation: Experience from a Tertiary Care Center.

Anatolian journal of cardiology·2026
Same author

Dynamic aortic stiffness response to exercise as a marker of functional capacity in early-stage heart failure.

Clinical physiology and functional imaging·2026
Same author

Impact of cardiohepatic syndrome on postoperative mortality in heart failure patients with reduced ejection fraction undergoing coronary artery bypass grafting.

Journal of cardiothoracic surgery·2026
Same author

Postinfarction Ventricular Septal Defect Despite Preserved Left Ventricular Function: Management Challenges and Procedural Complications.

JACC. Case reports·2026
Same author

Personalized Prediction of Left Ventricular Ejection Fraction in the Follow-Up of Patients with ST-Segment Elevation Myocardial Infarction: Development of a Practical Nomogram Model.

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir·2026

Related Experiment Video

Updated: May 5, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.5K

Varenicline-induced coronary thrombosis.

Arzu Kalayci1, Aysegul Eren, Gonenc Kocabay

  • 1Cardiology Department, Kartal Kosuyolu Heart and Research Hospital, Istanbul, Turkey.

The Annals of Pharmacotherapy
|November 22, 2013
PubMed
Summary

Varenicline, a smoking cessation aid, may increase the risk of heart attack. A case study suggests this drug likely caused acute coronary syndrome in a young, healthy man.

Keywords:
acute coronary syndromecoronary thrombosisvarenicline

More Related Videos

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

16.4K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K

Related Experiment Videos

Last Updated: May 5, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.5K
Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

16.4K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Varenicline (Champix, Chantix) is a widely used medication for smoking cessation, approved since 2006.
  • The drug has been linked to potential adverse cardiovascular events, with proposed mechanisms involving autonomic nervous system modulation, catecholamine release, and prothrombotic effects.

Observation:

  • A case report details a 30-year-old male with no prior cardiac history.
  • The patient experienced thrombotic occlusion of the left anterior descending artery, leading to acute coronary syndrome.

Findings:

  • The acute coronary syndrome was determined to be secondary to varenicline treatment.
  • The Naranjo probability scale strongly suggests varenicline as the probable cause of the myocardial infarction in this patient.

Implications:

  • This case highlights a potential serious cardiovascular risk associated with varenicline, even in younger individuals without pre-existing heart conditions.
  • Further investigation into the cardiovascular safety profile of varenicline is warranted.
  • Clinicians should carefully consider the cardiovascular risks and benefits when prescribing varenicline for smoking cessation.